Sobi North America Leadership Team

Sobi North America Leadership Team

Duane Barnes

Duane H. Barnes – President, Sobi North America

Employed since January 2021. MBA and MSc from Indiana University – Kelley School of Business, B.A. degree from West Virginia University. More than 30 years of experience spanning large pharma, biotech, payor and pharmacy in key executive and business development roles.  

Most recently President and Head of U.S. Operations at UCB BioPharma where he oversaw Government Affairs, Policy, Advocacy, Communications, Market Access, Contracting & Pricing, Payer Strategy, Operations Excellence and chaired the U.S. Leadership Team. Previous positions included executive roles at Amgen, Prime Therapeutics, Aetna, Medco Health Solutions, Merck-Medco and Quest Diagnostics.

Guled Adam

Guled H. Adam – General Counsel, Head of Legal, Ethics and Compliance, Sobi North America

Guled Adam is General Counsel for Sobi North America. In this role, he oversees all legal, ethics and compliance matters pertaining to the NA organization, serving as a member of the NA Leadership Team, Sobi’s global Legal Leadership Team and the Pricing and Incentive Compensation committees.

Guled’s legal career has focused exclusively in life sciences. He began in private practice representing some of the nation’s largest pharmaceutical companies in complex products liability and related litigation, before transitioning to senior in-house roles supporting a broad array of legal matters pertaining to commercialization, business development and strategic transactions, healthcare compliance, corporate governance, securities and disclosures, intellectual property, employment, and contracting. He joins Sobi NA from AgNovos where he served as General Counsel, Chief Compliance Officer and Secretary.

Guled earned a Bachelor of Arts degree in Political Science from the College of the Holy Cross in Massachusetts and his Juris Doctor degree from Syracuse University College of Law in New York.

Christine Belin

Christine Belin – Chief Financial Officer, North America

Employed since September 2014.  MBA - Johnson Graduate School of Management at Cornell University, BS in Chemical Engineering from Cornell University.  Over 15 years of experience in the pharmaceutical industry in a variety of finance leadership roles.

Previous positions: Director of Finance and Revenue Accounting at ARIAD Pharmaceuticals 2013-2014, Director of Commercial Financial Planning and Analysis at Human Genome Sciences 2010-2013 and various positions at Amgen from 2002 through 2010 including Director of Finance for Colorado Operations 2007-2010 and Senior Finance Manager of Europe R&D at Amgen, Ltd in Cambridge, UK 2005-2007.  Before Amgen, she worked as a reservoir engineer at Shell Exploration and Production Co.

Geoff Ebeling

Geoff Ebeling – Vice President, Head of U.S. Immunology Franchise

Employed since June 2019.  MBA – Harvard University, B.S. in Mechanical Engineering from the Massachusetts Institute of Technology. Significant pharmaceutical and biotech experience spanning program management, strategic planning, M&A and operational improvement.

Previous positions: Vice President, Corporate Integration and M&A Strategic Programs Lead at Shire.  Principal at Bain & Company, providing corporate and commercial strategy consultation and performance improvement to clients across healthcare and life sciences.

Matt Gurtis

Matt Gurtis – Vice President, Head of U.S. Synagis® Franchise

Matt Gurtis is Vice President and Head of the U.S. Synagis Franchise. In this role, he oversees all U.S. marketing and sales activities for the brand. 

Most recently, Matt served as National Senior Director Regional Payer Accounts. He joined Sobi in early 2019 as Regional Sales Director for the Florida, Georgia and Puerto Rico markets, and later served as Commercial Business Senior Director – Western U.S. He has 30 years’ experience in the pharmaceutical industry, holding several sales and marketing positions with Bayer, MedImmune and AstraZeneca. Matt has a successful track record in leading Sales and Market Access teams and is skilled in the therapeutic areas of rare disease, oncology, infectious disease, cardiovascular and metabolic, among others. His experience also includes hospital systems and large Integrated Delivery Networks, biotechnology and specialty distribution, national and regional payers, Medicaid, and Pharmacy Benefit Managers. 

Matt has Bachelor of Business Administration degree from Florida State University in Tallahassee. 

Nadège Houri – Vice President, Head Strategy and Business Optimization Sobi North America

Nadège Houri is Sobi North America’s Vice President, Head of Strategy and Business Optimization. In this role, Nadège leads the development and execution of Sobi NA’s business strategy, including merger and acquisition diligence, new product planning, and launch program management. Nadège works closely with the Global Strategy and Development team to ensure strategy alignment and execution excellence. 
Nadège joined Sobi from Janssen Pharmaceuticals where she held various global commercial roles, most recently leading the company’s retina gene therapy portfolio and key global strategies for Oncology and Rare diseases. Her experience also includes specialty and primary care, cardiovascular, immunology and medical devices with roles in commercial, marketing, and sales with Merck and Pfizer, and in management consulting leadership with McKinsey & Company. 
Nadège received a master’s degree in Management from the top-ranked ESCP Europe in Paris.

Bob Jahr

Bob Jahr – Chief Commercial Officer, Sobi North America

Bob joined Sobi North America as Chief Commercial Officer in May, 2021. In this role, he is responsible for overseeing and accelerating the North America commercial strategy as well as planning and executional excellence. He is accountable for all marketing, sales, operations and market access activities with a focus on driving and accelerate business growth in North America, ensuring an integrated commercial strategy and delivering optimal operational execution.

Bob has more than 20 years experience in the biopharmaceutical industry and has a deep understanding across therapeutic markets and geographies. He joins Sobi NA from UCB, where he served as Head of International Markets leading global teams including China, Japan, and Canada, and before that Head of U.S. Payer Strategy, Value, & Innovation developing teams during a period of expansion and launches. Prior to UCB he held leadership roles in sales, marketing, operations, payor strategy and market access at Amgen and Regeneron.

Bob received a Bachelor of Science and an MBA from the University of Montana.

Hank Kessler

Hank Kessler – Vice President, Head of Doptelet® Franchise, Sobi North America

Hank Kessler is Vice President, Head Doptelet® Franchise for Sobi North America. He is responsible for all commercial activities for the Doptelet franchise in North America, including strategy and all marketing and sales activities and execution.

Hank has 20 years of commercial leadership experience, which includes leading teams across marketing, sales, value and access while successfully launching 10 products spanning a variety of therapeutic areas. Prior to joining Sobi, Hank was with Amgen where he served most recently as the Value Strategy and Marketing Lead for the full portfolio. In this role, he was responsible for Amgen’s US Value-Based Partnerships, brand value propositions, above-brand thought leadership initiatives, and Integrated Delivery Network strategy. Hank also initiated and helped shape the company's focus on Social Determinants of Health to serve patients and participate in the healthcare ecosystem in unique ways. Before this role, Hank led the US Commercial integration for the company's acquisition of Otezla from Celgene/Bristol-Myers Squibb, played a key role in the build-out of Amgen's presence in the cardiovascular space and led the marketing teams for Amgen’s US cardiovascular brands. Previous to Amgen, Hank spent eight years at Bristol-Myers Squibb in various marketing and sales leadership roles in the Virology, Neuroscience, and Cardiovascular disease areas.

Hank has a MBA degree from the Tuck School of Business at Dartmouth College in New Hampshire, and a BA degree in History and Studies in the Environment from Yale University in Connecticut.

Reagan Klima

Reagan Klima – Vice President, Market Access and Government Affairs

Reagan Klima is Vice President, Market Access and Government Affairs for Sobi North America. In this role, she is responsible for overseeing and accelerating U.S. market access, developing strategy and implementation of innovative solutions to assure patient access to our rare disease treatments. Her accountabilities include all activities related to coverage, payment, provider solutions, contracting, access solutions and value-based arrangements.

Reagan has more than 20 years’ experience with proven success in pre-approval market readiness, product launches and growth throughout the product life cycle. Prior to joining Sobi, she served as the Head of U.S. Marketing Access at Kite Pharmaceuticals (Gilead) leading the oncology Market Access team. Her experience also includes leading Strategic Accounts & GPO at Incyte Corporation, and Account Manager and Market Access roles of increasing responsibility with Bayer, Johnson & Johnson, Biogen Idec, Eli Lilly, and KLS Martin LP.

Reagan earned a Master of Business Administration degree (MBA) with a Marketing concentration from Webster University in Missouri and a Bachelor of Science degree in Business Administration, Marketing and Management from the University of Missouri.

Bob McLay – Vice President, General Manager Canada

Employed since February 2016.  MBA - Auburn University, Auburn Alabama.  Bsc - University of Guelph, Guelph, Ontario.  Over 23 years of experience in the pharmaceutical industry with multiple leadership roles in marketing, sales, patient access, supply chain, trade relations and business development.

Previous positions: Multiple senior level positions with both large and small pharmaceutical companies.  Most recently, VP Sales and Marketing & Canadian Commercial Lead at Merus Labs International (2014-2015), Director of Sales at Takeda Canada (2012-2013), Marketing Director at Graceway Pharmaceuticals (2007-2012), Associate Sales Director and other various sales and marketing roles at Pfizer Canada (1994-2007)

Kate Thota

Kate Thota – Vice President, Commercial Experience, Innovation & Operations

Kate Thota is Vice President, Commercial Innovation & Operations, for Sobi North America. In this role, she is responsible for digital strategy, customer experience and digital ecosystem, marketing operations, commercial effectiveness, CRM and customer engagement tools.

Prior to joining Sobi, Kate was an Executive with Vynamic, a healthcare management consulting firm focused on brand strategy, launch excellence, commercial operations and integration. Her clients included Shire, Takeda, bluebird bio and Biogen. Her career also included leading high tech functions at EMC and Yahoo, Inc. and partnering with a broad range of healthcare clients in management consulting positions at Accenture and Capgemini.

Kate earned a Bachelor of Arts degree in Urban Planning from University of California San Diego. She also is credentialed in Customer Experience Innovation from Northwestern University, Organizational Design for Digital Transformation from Massachusetts Institute of Technology’s Sloan School of Management and Building Financial Acumen from Duke Corporate Education.

John Yee

John Yee, MD, MPH – Chief Medical Officer, North America

Employed since April 2020.  A.B. in History and Science from Harvard College; M.D. from Harvard Medical School; M.P.H. from the Harvard T.H. Chan School of Public Health.  Over 20 years of progressive leadership experience in academia and industry, with experience leading the launch of multiple new drugs across therapeutic areas in orphan, ultra-orphan and more prevalent diseases.

Previous positions: Multiple leadership positions within Genzyme (2003-2011), AstraZeneca (2011-2016), Intarcia Therapeutics (2016-2017), Vertex Pharmaceuticals (2017-2019) and Flexion Therapeutics.  Completed a residency in pediatrics and fellowships in immunology/rheumatology and health services research at Boston Children’s Hospital and served on the faculty at Boston Children’s Hospital and Harvard Medical School prior to industry leadership roles.